Marksans Pharma Limited Stock

Equities

MARKSANS

INE750C01026

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:48 2024-05-02 am EDT 5-day change 1st Jan Change
167.6 INR +1.09% Intraday chart for Marksans Pharma Limited -1.30% +4.03%
Sales 2024 * 21.58B 259M Sales 2025 * 26.33B 316M Capitalization 75.95B 910M
Net income 2024 * 3.34B 39.98M Net income 2025 * 4.07B 48.74M EV / Sales 2024 * 3.52 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.88 x
P/E ratio 2024 *
22.8 x
P/E ratio 2025 *
18.7 x
Employees 852
Yield 2024 *
-
Yield 2025 *
-
Free-Float 55.99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.09%
1 week-1.30%
Current month+10.34%
1 month+6.08%
3 months+14.01%
6 months+60.61%
Current year+4.03%
More quotes
1 week
165.05
Extreme 165.05
173.80
1 month
152.00
Extreme 152
185.50
Current year
130.25
Extreme 130.25
185.50
1 year
70.55
Extreme 70.55
185.50
3 years
38.60
Extreme 38.6
185.50
5 years
9.85
Extreme 9.85
185.50
10 years
9.85
Extreme 9.85
185.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 92-04-15
Director of Finance/CFO 54 02-09-05
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 49 21-08-10
Chief Executive Officer 52 92-04-15
Director/Board Member 52 14-09-24
More insiders
Date Price Change Volume
24-05-02 167.6 +1.09% 1,458,239
24-04-30 165.8 -1.98% 1,263,704
24-04-29 169.2 -1.74% 871,883
24-04-26 172.2 +2.99% 2,110,794
24-04-25 167.2 -0.59% 1,037,336

Delayed Quote NSE India S.E., May 02, 2024 at 07:43 am EDT

More quotes
Marksans Pharma Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The Company produces goods across various therapeutic areas, such as pain management, cough and cold, cardiovascular and central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic, among others. The Company operates four manufacturing facilities across India, the United Kingdom and the United States. The Company manufactures oral solid tablets, soft gelatin capsules and hard capsules in Goa. It also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The Company has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
167.6
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. MARKSANS Stock